Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
My main bugbear with patents and it's not just SAR that do it, most do. It's sometimes really difficult to track down if they have a patent or not. It's fundamental to know this so you can make an informed judgment to invest. I do understand the issue though. If you expect the SP to go up on applying for a patent then you have to accept that the SP will go down when\if it's rejected. IMO this is why Sareum only RNS when a patent has been granted.
Great find Citizen. Where we differ from our rivals though is that whilst we could be issuing an RNS to increase the investor hunger and awareness in Sareum we don't. Here's a recent patent application announcement RNS from N4P below, which shows how to drip drip drip announcements to the investor community. I just wish Tim and Stephen would do the same. Good luck, Brighty
As announced on 15 November 2018, the Company filed a Patent Cooperation Treaty ("PCT") patent application for improvements made to the manufacturing process for its Nuvec® system. Under the terms of the PCT application process and following conclusion of the national phasing, the Company is now required to make specific applications in the territories in which it wishes to gain patent protection.
In consideration of this, the Company is filing ongoing patent applications in the following territories: Europe (including the UK); USA; Japan; India; Australia; Canada; and China. These additional applications, if successful, claim priority from the Company's United Kingdom patent application number 1718817.8.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are seeking additional protection in the territories listed above, which the Board believes would provide maximum patent coverage for our PCT application whilst minimising outgoing expenditure. If the patents are granted in these regions, the Company will maintain its strong commercial protection of Nuvec®."
Indeed Stoney,
Gives us something to ponder or dream about I guess, I ended up here the other day too:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PTXT&s1=gilead&OS=gilead&RS=gilead
Last updated 15.09.2020..... something or nothing again, but we never know................ sometimes, 2+2 does = 4....
All the best
The patent is for crystalline form of a compound.
This may well be related to our FLT3. The following is a description of crystalline form
Polymorphs are different crystalline forms (at different free energy states) of the same molecule or molecules. ... The nature of the crystalline form of a drug substance may affect its stability in the solid state, its solution properties and its absorption.
Looks like it’s referring to the solubility of a drug which we know SAR had trouble with earlier. Therefore, as suggested by other posters this may be the registration of the ‘fixed’ compound.
GLA
Hi All
Intriguing issue this new patent, I have tried to dig around but came up with nothing. The only difference to all previous patents is that this is a GB registered patent. All of our previous applications whether granted or not have been EU/US/JP and CN (which is Europe, USA, Japan and China).
I was thinking it may be connected to Brexit but this has also drawn a blank as all EU patents granted before Brexit stand.
Any further thoughts??
GLA
My interpretation of this patent is as follows:-
Flt +3 on its own, was originally granted a patent ( 2013 from memory could be wrong)
It is also allowed by sareum in their terms, that the undisclosed pharma can develop derivatives from this compound, ie a similar compound from the same family. This can lead to problems when a company tries to protect its intellectual rights and compounds, You only have to look at TYK2 with 1801 and 1802. Similar, but not identical compounds which are protected by the same patent. A new patent for 1801 is proving very difficult to obtain ( I will not hold my breath on this one).
Maximum protection of a compound by a patent is paramount to maximise the worth of the compound. The longer the remaining patent protection time the better.
I am pretty confident Sareum will receive the 900k in January as is Tim ( his last interview with the smooth aussie). Sareum does need the solubility issue to be resolved to receive the milestone payment, only for the Chinese pharma to continue development.
Flt+3 showed excellent A.D.M.E results in its early days. In addition, I will also add, that formulation issues prevented the manufacture of sufficient quantities, to establish a MTD. ( ie completion of toxicology studies) good tolerance of the candidate drug and no significant side effects seen.
Do not underestimate the value of this compound.
Do not underestimate the value of SRA737
Last and not least Sareum own wholly Tyk 2 1801 and 1802.
Yes, it does take time for a compound to reach fruition as many of us here are aware and I have not been here as long as some. Final stages of negotiations takes months, many months. We can only wait for news. Our problem is we don't know when we will receive.
Our next information is due in October with regards to a grant for Covid -19. Care to put a price on that?
Three months ago things were looking good with regards to Covid. Current measures now put in place suggest that is no longer the case.
If Tim thinks that the Tyk2 1801 can target a cytokine storm better than other treatments used then so much the better. He is a chemist after all and not a salesman.
We all at sometime have been a peeved with Sareum.
Easier said than done, but patience will pay off.
Regards all.
Hi RMM, cheers for your thoughts, wouldn't we have patented this in the same way prior to the deal with Hebei Medical University Biomedical Engineering Center (HMUBEC)? - Maybe John & tim tweaked the molecule into something new following the data pack returned from HMUBEC...More intrigue as always with Sareum. All the best
I'm no expert in Patent Law but I do know that you file for patent protection before handing anything over to a third party. What is interesting is that the Publication Number ends in DO. This means that only the title, assignee and application number are revealed. If the product is under development then you can secure your rights with a patent application(which in this case cites a previous patent) and supply the details at a later stage - up to 18 months later. I think its just JR protecting what the outcome could be in 9 months (now 3 months) time. GLA
What I mean about the dates is that it was too early to know by then? Unless they already knew and had already proved it could be done. But if that, why the 9-month window? Is this filing just getting ahead of the game? Getting in the queue as it were and by the time it is assessed, the Chinese will know for sure if they have solved the issue.
Dates Match
FLT3+Aurora Inhibitors The Licensee (a China-based specialty pharmaceutical company) confirmed receipt of the programme data on 7 April 2020
2020-04-07 Application filed by SAREUM Ltd
2020-04-07 Priority to GBGB2005114.0A
2020-05-20 Publication of GB202005114D0
Status Pending
Think I will drop John Reader a line and ask what The patent is for. It’s in the public domain after all?
Maybe Fadec will be able to find more. The optimist in me says this is for Aurora and they cracked solubility but the dates don't add up.
Nice one citizen, i dont think anyone has posted that patent application yet or i missed it. Interesting but can't see much application details so would like to know what compound it comes out of if any the researchers know more or have a feeling re the science?
Morning All,
As always, forever digging around Sareum/TYK2, FLT3 etc etc.
Stumbled across a patent application for earlier this year - might be something, might be nothing, just thought I'd share, (apologies if already mentioned on here):
20 May 2020
(Journal 6835) GB2005114.0 Applicant: Sareum Limited
Title: Crystalline Forms of a Pharmaceutical Compound
Date Lodged: 7 April 2020
https://patents.google.com/patent/GB202005114D0/en?assignee=SAREUM+Ltd&sort=new